Logo image of 1DXCM.MI

DEXCOM INC (1DXCM.MI) Stock Overview

Europe - BIT:1DXCM - US2521311074 - Common Stock

59.05 EUR
-1.69 (-2.78%)
Last: 10/28/2025, 7:00:00 PM

1DXCM.MI Key Statistics, Chart & Performance

Key Statistics
Market Cap23.16B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Shares392.16M
Float390.48M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)1.46
PE40.45
Fwd PE26.14
Earnings (Next)10-30 2025-10-30/amc
IPO2005-04-14
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


1DXCM.MI short term performance overview.The bars show the price performance of 1DXCM.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0.1 0.2 0.3 0.4 0.5

1DXCM.MI long term performance overview.The bars show the price performance of 1DXCM.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 1DXCM.MI is 59.05 EUR.

DEXCOM INC / 1DXCM Daily stock chart

1DXCM.MI Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABL.DE ABBOTT LABORATORIES 24.97 186.44B
IUI1.DE INTUITIVE SURGICAL INC 63.2 167.66B
1ISRG.MI INTUITIVE SURGICAL INC 54.14 143.61B
BSX.DE BOSTON SCIENTIFIC CORP 34.25 128.91B
1BSX.MI BOSTON SCIENTIFIC CORP 35.31 127.13B
2M6.DE MEDTRONIC PLC 16.95 103.27B
SHL.DE SIEMENS HEALTHINEERS AG 20.66 55.45B
BOX.DE BECTON DICKINSON AND CO 12.94 45.52B
EWL.DE EDWARDS LIFESCIENCES CORP 31.72 41.16B
1PHIA.MI KONINKLIJKE PHILIPS NV 17.04 23.63B
DC4.DE DEXCOM INC 40.26 23.05B
PHI1.DE KONINKLIJKE PHILIPS NV 16.31 22.62B

About 1DXCM.MI

Company Profile

1DXCM logo image DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

Company Info

DEXCOM INC

6340 Sequence Drive

San Diego CALIFORNIA US

Employees: 10250

1DXCM Company Website

1DXCM Investor Relations

Phone: 18582000200

DEXCOM INC / 1DXCM.MI FAQ

Can you describe the business of DEXCOM INC?

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.


What is the current price of 1DXCM stock?

The current stock price of 1DXCM.MI is 59.05 EUR. The price decreased by -2.78% in the last trading session.


Does 1DXCM stock pay dividends?

1DXCM.MI does not pay a dividend.


What is the ChartMill rating of DEXCOM INC stock?

1DXCM.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Would investing in DEXCOM INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1DXCM.MI.


1DXCM.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1DXCM.MI.


Chartmill TA Rating
Chartmill Setup Rating

1DXCM.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1DXCM.MI. While 1DXCM.MI has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1DXCM.MI Financial Highlights

Over the last trailing twelve months 1DXCM.MI reported a non-GAAP Earnings per Share(EPS) of 1.46. The EPS decreased by -2.86% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.29%
ROA 7.8%
ROE 22.21%
Debt/Equity 0.5
Chartmill High Growth Momentum
EPS Q2Q%11.63%
Sales Q2Q%15.21%
EPS 1Y (TTM)-2.86%
Revenue 1Y (TTM)9.3%

1DXCM.MI Forecast & Estimates

For the next year, analysts expect an EPS growth of 26.84% and a revenue growth 14.99% for 1DXCM.MI


Analysts
Analysts84.57
Price TargetN/A
EPS Next Y26.84%
Revenue Next Year14.99%

1DXCM.MI Ownership

Ownership
Inst Owners97.73%
Ins Owners0.19%
Short Float %N/A
Short RatioN/A